Uveal Melanoma Survival Rate: What Shapes Your Prognosis

Most people treated for uveal melanoma are alive five years later. In US national cancer statistics, the uveal melanoma survival rate at five years — the 5-year relative survival rate — is about 84% for all stages combined and about 88% when the melanoma is still confined to the eye. For many patients the eye tumor is controlled and the cancer never returns; for others it spreads, most often to the liver, sometimes many years after successful treatment of the eye.

This page explains what the uveal melanoma survival rate figures mean, which factors shape an individual prognosis, and how to approach questions about life expectancy. Statistics describe groups of people treated in the past; they cannot predict what will happen to any one person. For diagnosis and treatment, see the main uveal melanoma page.

What is the uveal melanoma survival rate?

Survival is usually reported as 5-year relative survival. This compares people with the cancer with people of the same age and sex in the general population, so it largely filters out deaths from unrelated causes. The American Cancer Society reports the following figures for eye melanoma, based on US patients diagnosed in 2015–2021:

Two points help put these numbers in context. First, most people are diagnosed at the localized stage; detectable distant metastases are present at diagnosis in only about 2–3% of patients. Second, the figures come from people diagnosed several years ago and do not fully reflect newer treatments for metastatic disease.

US registry data also show that 5-year relative survival (about 83%) has barely changed in four decades, while treatment moved from removing the eye to radiation: keeping the eye has not reduced survival, but spread beyond the eye remains the main challenge.

How likely is uveal melanoma to spread?

Uveal melanoma spreads through the bloodstream rather than the lymph nodes, and the liver is involved in about 9 out of 10 people whose melanoma spreads. Across all tumor sizes, about 25% of patients develop metastases within 5 years and about 34% within 10 years, and patient-education sources note that the proportion approaches half with longer follow-up. Put the other way, two in three patients show no sign of spread ten years after diagnosis.

Timing varies. Metastases often appear in the first years after diagnosis, but they can emerge a decade or more later; tumors with an SF3B1 gene change are characteristically late spreaders, often after five years. This is why current guidelines continue liver surveillance up to year 10.

What influences prognosis?

Specialists estimate each person's risk from a combination of clinical, pathological and genetic factors.

Tumor size

Size is the most widely available predictor. In published series, the 5-year risk of metastasis rose steadily with tumor thickness:

This is one reason why growing lesions are treated early. Results of the Collaborative Ocular Melanoma Study (COMS), reported by size group, point the same way, although they use different measures and time points:

COMS figures come from patients treated before routine genetic testing and today's treatments for metastatic disease were available, and the all-cause figure also includes deaths from unrelated illness.

Location in the eye

Iris melanomas have the most favorable outlook: about 3% spread within 5 years, 5% within 10 years and 10% within 20 years, and 5-year survival exceeds 95%. Tumors that involve the ciliary body carry a higher risk than those limited to the choroid, which is why ciliary body involvement raises the stage. More on the iris melanoma page and on eye cancer stages.

Genetic profile of the tumor

When a biopsy is taken, genetic tests on the tumor cells estimate risk more precisely than size alone. Gene expression profiling sorts tumors into classes with very different 5-year risks of metastasis:

Expression of a gene called PRAME raises the risk within each class, and loss of one copy of chromosome 3 (monosomy 3) or of the BAP1 gene signals a higher risk. How these tests are done, and what each result means, is explained on biopsy and genetic testing.

Other features

Pathology adds further information. Tumors made of epithelioid cells behave more aggressively than those made of spindle cells, and growth through the eye wall (extraocular extension) or a tumor margin close to the front of the eye increases the risk.

Does the choice of treatment affect survival?

For medium-sized tumors, the COMS trial randomly assigned patients to plaque radiotherapy or removal of the eye. At 12 years, melanoma-related mortality was 17% after enucleation and 21% after plaque — a difference that was not statistically significant, although a 2025 analysis points out that the trial was not designed to rule out small differences. For large tumors, radiation given before enucleation did not improve survival either. On current evidence, choosing to keep the eye does not lower your chances.

What does this mean for life expectancy?

"How long do I have?" is one of the first questions many people with choroidal melanoma ask, and it deserves a careful, honest answer. For most people whose melanoma is confined to the eye, the outlook is good: two in three remain free of metastases ten years after diagnosis, and a small class 1A tumor carries a risk of spread of about 2% over five years. A large class 2 tumor carries a much higher risk. No statistic, however, can say what will happen to one individual.

If the melanoma does spread, survival depends on how much of the liver is involved, how the disease responds to treatment and the person's overall health. Survival after spread has historically been limited, but it is improving. In the phase 3 trial of tebentafusp for patients who are HLA-A*02:01-positive, median survival was 21.6 months compared with 16.9 months with other treatments, and 16% versus 8% of patients were alive after five years. The follow-up and metastasis page describes current options.

People differ in how much detail they want: some prefer precise numbers, others would rather focus on the plan. Both are reasonable, and it is fine to ask for information at your own pace.

Can anything improve the outlook?

There is no proven way yet to prevent metastasis once the eye has been treated, but several things make a real difference:

• Early assessment of suspicious lesions. Because the risk rises with tumor thickness, a pigmented lesion that is growing or has risk features should be assessed promptly — see choroidal nevus.
• Risk-based surveillance. Under the 2026 NCCN guideline, liver imaging ranges from every 3–6 months for high-risk patients to yearly for low-risk patients, continuing for up to 10 years. The aim is to find any spread while it is limited and more treatments are possible.
• Clinical trials. Studies are testing drug treatment given after eye therapy to high-risk patients; as of September 2026 this approach is investigational.
• A clear record. Keeping copies of scans, pathology and genetic reports makes it easier to obtain a second opinion or continue care in another country.